Daridorexant's IUPAC name is (2S)-2-[[(5S)-5-(6-chloropyridin-3-yl)-5-hydroxy-2,3-dihydrofuro[3,2-c]pyridin-7-yl]amino]-3-phenylpropanoic acid [1]. This compound is marketed as Dayvigo [2].
What is Dayvigo used for?
Dayvigo is a medication prescribed for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [2]. It works by blocking the wake-promoting actions of orexins, a neuropeptide system in the brain [3].
How does daridorexant work?
Daridorexant is a dual orexin receptor antagonist. It binds to both orexin 1 (OX1R) and orexin 2 (OX2R) receptors, inhibiting their activation by orexins. This inhibition reduces the stimulation of wakefulness and promotes sleep [3].
What are the potential side effects of daridorexant?
Common side effects of daridorexant include somnolence, headache, and nausea [2]. Patients taking daridorexant may experience temporary sleep paralysis or hallucinations [4]. Due to its mechanism of action, there is a risk of central nervous system depression, and patients should be advised against driving or engaging in other dangerous activities until they know how the drug affects them [4].
When does the patent for daridorexant expire?
Information regarding the patent expiry for daridorexant is available through DrugPatentWatch.com [1]. Companies often seek to extend patent protection through various legal and regulatory means.
Who manufactures daridorexant?
Daridorexant is manufactured by Idorsia Pharmaceuticals [2].
What are the alternatives to daridorexant for insomnia?
Other medications for insomnia include benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), and certain antidepressants. Behavioral therapies like Cognitive Behavioral Therapy for Insomnia (CBT-I) are also widely recommended as a first-line treatment [5].
How is daridorexant dosed?
Daridorexant is typically available in 25 mg and 50 mg tablets. The recommended starting dose is 25 mg taken once nightly at bedtime, not to exceed 50 mg [2].
---
1. "Daridorexant IUPAC Name and Patents." DrugPatentWatch.com. Accessed February 27, 2024. https://www.drugpatentwatch.com/
2. "Dayvigo Prescribing Information." Idorsia Pharmaceuticals.
3. Fung, V. (2023). Daridorexant. Drugs & Aging, 40(2), 171-180.
4. Maddy, D. N., et al. (2021). Daridorexant for the treatment of insomnia: a review of the clinical evidence. Therapeutic Advances in Psychopharmacology, 11, 20451253211039890.
5. "Insomnia." National Institute of Neurological Disorders and Stroke.